Dr. Reddy's Laboratories per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹33.61₹50.41₹67.89₹335.22₹271.47
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹33.59₹50.35₹67.79₹334.59₹270.90
₹453.79₹453.79₹402.27₹1,698.05₹1,397.73
₹396.38₹403.60₹391.41₹1,683.41₹1,480.77
—₹67.95₹55.67₹273.04₹353.38
₹21.95₹21.95₹14.42₹108.16₹240.15
—₹7.97₹7.99₹39.95₹29.89
83.583.583.416.616.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS271.47335.2267.8950.4133.61
Diluted EPS270.90334.5967.7950.3533.59
Book Value per Share1,397.731,698.05402.27453.79453.79
Revenue per Share1,480.771,683.41391.41403.60396.38
Cash Flow per Share353.38273.0455.6767.95—
Free Cash Flow per Share240.15108.1614.4221.9521.95
Dividends per Share29.8939.957.997.97—
Shares Outstanding (cr)16.716.683.483.583.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.